Are there known biomarkers predictive of response or resistance to sacituzumab govitecan which should be incorporated into treatment decisions for metastatic TNBC?

In the ASCENT trial, we evaluate the association between Trop-2 expression and clinical outcomes. Overall, the median progression-free survival (PFS) was 6.9, 5.6, and 2.7 months for high, medium, and low Trop-2 scores, respectively with SG compared with 2.5, 2.2, and 1.6 months with standard chemot...

Sacituzumab govitecan is a relatively new drug, so the pattern of resistance is not completely understood. Recently, Dr. @Dr. First Last and Dr. Ellisen shared data that they have identified two alterations thought to be linked to sacituzumab resistance. They did this by looking at pre-sacituzumab b...